carbidopa and malondialdehyde

carbidopa has been researched along with malondialdehyde in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (50.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Ahlskog, JE; Kokmen, E; Low, PA; Nickander, KK; Petersen, RC; Tyce, GM; Uitti, RJ	1
Farag, NE; Hammad, LN; Zaitone, SA	1

Other Studies

2 other study(ies) available for carbidopa and malondialdehyde

Article	Year
No evidence for systemic oxidant stress in Parkinson's or Alzheimer's disease. Movement disorders : official journal of the Movement Disorder Society, 1995, Volume: 10, Issue:5 Topics: Aged; Alzheimer Disease; Antiparkinson Agents; Brain; Cabergoline; Carbidopa; Diabetes Mellitus; Ergolines; Female; Free Radicals; Humans; Levodopa; Lipid Peroxidation; Male; Malondialdehyde; Oxidative Stress; Parkinson Disease; Selegiline; Vitamin E	1995
Antioxidant potential of melatonin enhances the response to L-dopa in 1-methyl 4-phenyl 1,2,3,6-tetrahydropyridine-parkinsonian mice. Pharmacological reports : PR, 2013, Volume: 65, Issue:5 Topics: Animals; Antioxidants; Antiparkinson Agents; Basal Ganglia; Behavior, Animal; Carbidopa; Catalase; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Drug Synergism; Glutathione; Glutathione Peroxidase; Levodopa; Lipid Peroxidation; Male; Malondialdehyde; Melatonin; Mice; Motor Activity; Oxidative Stress; Parkinsonian Disorders; Superoxide Dismutase	2013

Article

Year

No evidence for systemic oxidant stress in Parkinson's or Alzheimer's disease.

Movement disorders : official journal of the Movement Disorder Society, 1995, Volume: 10, Issue:5

Topics: Aged; Alzheimer Disease; Antiparkinson Agents; Brain; Cabergoline; Carbidopa; Diabetes Mellitus; Ergolines; Female; Free Radicals; Humans; Levodopa; Lipid Peroxidation; Male; Malondialdehyde; Oxidative Stress; Parkinson Disease; Selegiline; Vitamin E

1995

Antioxidant potential of melatonin enhances the response to L-dopa in 1-methyl 4-phenyl 1,2,3,6-tetrahydropyridine-parkinsonian mice.

Pharmacological reports : PR, 2013, Volume: 65, Issue:5

Topics: Animals; Antioxidants; Antiparkinson Agents; Basal Ganglia; Behavior, Animal; Carbidopa; Catalase; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Drug Synergism; Glutathione; Glutathione Peroxidase; Levodopa; Lipid Peroxidation; Male; Malondialdehyde; Melatonin; Mice; Motor Activity; Oxidative Stress; Parkinsonian Disorders; Superoxide Dismutase

2013